NYSE
$18.20▼ 1.78%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.29BShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 1d agoAfter-hours26.10.24 05:128-KKey event#●●●#●●●
Arcus Biosciences, Inc.
Arcus Biosciences completed a public offering of 16,428,572 shares of common stock at a price of $17.50 per share on October 23, 2026. The company raised approximately $269.7 million in net proceeds through this offering, which included the full exercise of the underwriters' option.…more
$18.20-1.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 2d agoAfter-hours26.10.23 05:05424B5Offering
Arcus Biosciences, Inc.
Arcus Biosciences is conducting a common stock offering of 14,285,715 shares at $17.50 per share, raising approximately $250 million in gross proceeds. The company intends to use the net proceeds to accelerate the clinical development of casdatifan and for general corporate purposes, with underwriters granted a 30-day option to purchase additional shares.…more
$18.20-1.78%vs prev closeView filingShare - 3d agoAfter-hours26.10.22 05:30424B5Offering
Arcus Biosciences, Inc.
Arcus Biosciences (RCUS) has filed a preliminary prospectus supplement for a common stock offering. The company estimates it held approximately $694.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026, and intends to use the net proceeds to accelerate the clinical development of casdatifan and for general corporate purposes.…more
$18.20-1.78%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoOvernight26.10.22 16:40Bullish#●●●#●●●#●●●
Arcus Biosciences Prices $250M Public Offering
Arcus Biosciences has priced a public offering of 14,285,715 common shares at $17.50 per share. The company expects to raise approximately $250 million in gross proceeds from this offering.…more
$18.20-1.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 3d agoAfter-hours26.10.22 05:28
●●●●●●●● ●●●●● ●●●●●●
Arcus Biosciences has announced the commencement of an underwritten public offering of its common stock. This equity offering may lead to the dilution of existing shareholders' stakes.…more
$18.20-1.78%vs prev closeShareBenzinga - 5d agoPre-market26.10.20 21:38
●●●●●●●● ●●●●● ●●●●●●
Arcus Biosciences announced that its kidney cancer drug candidate, casdatifan, demonstrated superior survival outcomes compared to existing benchmarks in clinical trials. The company is currently advancing Phase 3 studies to further validate its potential as a treatment.…more
$18.20-1.78%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report